Dat	e:December		
You	ır Name:Mo Lyu		
Ma	nuscript Title: A transo	criptomic analysis based o	n aberrant methylation levels revealed potential novel
the	rapeutic targets for nasopha	aryngeal carcinoma	
Ma	nuscript number (if known):	, '	
	•		
rela par to t	ated to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	e following questions apply t nuscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present		premiing or the work
1	All support for the present		
	manuscript la a funding	None	
	manuscript (e.g., funding,	ivone	
	provision of study materials,	None	
	provision of study materials, medical writing, article	None	
	provision of study materials, medical writing, article processing charges, etc.)	None	
	provision of study materials, medical writing, article	None	
	provision of study materials, medical writing, article processing charges, etc.)	None	
	provision of study materials, medical writing, article processing charges, etc.)		t 26 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: pas	t 36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from		t 36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months
2	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: pas	t 36 months
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months
	provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas	t 36 months

				_
5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
_	educational events	Nene		
6	Payment for expert testimony	None		
	testimony			_
7	Support for attending	None		
,	meetings and/or travel			
	-			
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
10	Advisory Board			
10	Leadership or fiduciary role in other board, society,	None		
	committee or advocacy			
	group, paid or unpaid			
11	Stock or stock options	None		
_				
12	Receipt of equipment,	None		
	materials, drugs, medical		_	
	writing, gifts or other services			
13	Other financial or non-	None		_
13	financial interests	None		
Plea	ase summarize the above co	nflict of interest in the fo	llowing box:	
N	lone.			
- 1				

Dat	e:December		
You	ır Name:Xinzhu Yi		
Ma	nuscript Title: A transo	criptomic analysis based o	n aberrant methylation levels revealed potential novel
the	rapeutic targets for nasopha	aryngeal carcinoma	
Ma	nuscript number (if known):	, '	
rela par to t	ated to the content of your r ties whose interests may be	manuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	e following questions apply t nuscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
to t	•	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	institution
		needed)	
		needed) Time frame: Since the initia	al planning of the work
1	All accorded for the process	Time frame: Since the initia	al planning of the work
1	All support for the present	-	al planning of the work
1	manuscript (e.g., funding,	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials,	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initia	al planning of the work
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Time frame: Since the initia	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Time frame: Since the inition None Time frame: pas	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Time frame: Since the initia	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: Since the inition None Time frame: pas	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: Since the initial None Time frame: pas None	
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Time frame: Since the inition None Time frame: pas	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: Since the initial None Time frame: pas None	
2	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: Since the initial None Time frame: pas None	

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Commont for attending	News	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fo	lowing box:
N	lone.		

Date	e:December 7,2021		
	r Name:Zhiwei Huang_		
			n aberrant methylation levels revealed potential novel
Mar	nuscript number (if known):		
related to the man to the median	ted to the content of your name ies whose interests may be cansparency and does not not interest, it following questions apply the content only. author's relationships/actions e epidemiology of hyperterication, even if that medical	nanuscript. "Related" mean affected by the content of ecessarily indicate a bias. It is preferable that you do not the author's relationship wities/interests should be not not mentioned in the author is not mentioned	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other items,
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		т: С	1 26 mantha
2	Grants or contracts from	Time frame: pas	t 36 months
_	any entity (if not indicated	NOTIE	
	in item #1 above).		+
3	Royalties or licenses	None	

Consulting fees

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	None	
	illialicial lifterests		
Dlar	aca cummariza tha abaya ca	nflict of interest in the f	ollowing how
FIE	ase summarize the above co	muct of interest in the I	onowing box.
	None.		
"	vone.		

Date	e:December 7,2021		
You	r Name:Yirong Chen		
		-	n aberrant methylation levels revealed potential novel
Mar	nuscript number (if known):		
relate part to trelate man. The to the med.	ted to the content of your name ies whose interests may be cansparency and does not not ionship/activity/interest, it following questions apply touscript only. author's relationships/activity ended in the properties of the prop	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. it is preferable that you do to the author's relationship wities/interests should be insion, you should declare ition is not mentioned in the	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript pertains all relationships with manufacturers of antihypertensive
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
		relationship or indicate none (add rows as	institution)
		needed) Time frame: Since the initia	al planning of the work
1	All support for the present	None None	ar planning of the work
_	manuscript (e.g., funding,	None	
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
		Time frame: pas	t 36 months
2	Grants or contracts from	None	
	any entity (if not indicated		
2	in item #1 above).	Ness	
3	Royalties or licenses	None	

Consulting fees

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	News	
6	Payment for expert	None	
	testimony		
7	Commont for attending	News	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fo	lowing box:
N	lone.		

Date	e:December 7,2021		
You	r Name:Zhu Ai		
Man	uscript Title: A transc	criptomic analysis based o	n aberrant methylation levels revealed potential novel
ther	apeutic targets for nasopha	ryngeal carcinoma	
Man	uscript number (if known):		
relat	ted to the content of your n	nanuscript. "Related" mea	relationships/activities/interests listed below that are any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment
to tr	_	ecessarily indicate a bias.	If you are in doubt about whether to list a
	following questions apply touscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed) Time frame: Since the initial	al planning of the work
1	All support for the present	None None	ar planning of the work
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article		
	processing charges, etc.)		
	No time limit for this item.		
2		Time frame: pas	t 36 months
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
	ubovcj.	1	1
3	Royalties or licenses	None	

4

Consulting fees

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	None	
	illialicial lifterests		
Dlar	aca cummariza tha abaya ca	nflict of interest in the f	ollowing how
FIE	ase summarize the above co	muct of interest in the I	onowing box.
	None.		
"	vone.		

e:December		
r Name:Yuying Liang		
nuscript Title: A transc	criptomic analysis based o	n aberrant methylation levels revealed potential novel
apeutic targets for nasopha	ryngeal carcinoma	
nuscript number (if known):		
ted to the content of your n ies whose interests may be ansparency and does not n	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
lication, even if that medica	ntion is not mentioned in t	•
	whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		al planning of the work
		ar planning of the work
manuscript (e.g., funding, provision of study materials, medical writing, article	None	
processing charges, etc.)		
No time limit for this item.		
		t 36 months
	None	
	None	
royalties of licenses	None	
	rapeutic targets for nasopharuscript number (if known): ne interest of transparency, ted to the content of your naies whose interests may be ransparency and does not nationship/activity/interest, it following questions apply transcript only. author's relationships/activity epidemiology of hypertellication, even if that medical em #1 below, report all supptime frame for disclosure is All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	r Name:Yuying Liang

5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	None	
	testimony		
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	None	
13	financial interests	None	
	illialicial lifterests		
Dlar	aca cummariza tha abaya ca	nflict of interest in the f	ollowing how
FIE	ase summarize the above co	muct of interest in the I	onowing box.
	None.		
"	vone.		

Dat	e:December		
You	ır Name:Qili Feng		
Ma	nuscript Title: A transc	criptomic analysis based o	n aberrant methylation levels revealed potential novel
the	rapeutic targets for nasopha	aryngeal carcinoma	
Ma	nuscript number (if known):		
In t	he interest of transparency	we ask you to disclose all	relationships/activities/interests listed below that are
rela par	ated to the content of your r ties whose interests may be	nanuscript. "Related" mea affected by the content o	ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a
rela	ationship/activity/interest, i	t is preferable that you do	so.
	e following questions apply t nuscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to t		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	tem #1 below, report all sup time frame for disclosure is	•	d in this manuscript without time limit. For all other item
		Name all entities with	Specifications/Comments
		whom you have this	(e.g., if payments were made to you or to your
		relationship or indicate	institution)
		none (add rows as	motitudion)
		needed)	
		Time frame: Since the initia	al planning of the work
1	All support for the present	None	
_	manuscript (e.g., funding,		
	provision of study materials,		
	medical writing, article processing charges, etc.)		
	medical writing, article		
	medical writing, article processing charges, etc.)		
	medical writing, article processing charges, etc.)		
	medical writing, article processing charges, etc.)	Time frame: pas	t 36 months
2	medical writing, article processing charges, etc.) No time limit for this item.	Time frame: pas	t 36 months
2	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from	Time frame: pas	t 36 months
2	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months
2	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None	t 36 months
2	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated		t 36 months
	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None	t 36 months
	medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	None	t 36 months

	•		
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	Nama	
6	Payment for expert	None	
	testimony		
7	Commont for attending	Nama	
7	Support for attending meetings and/or travel	None	
8	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
_	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		
12	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	None	
	financial interests		
Plea	ase summarize the above co	nflict of interest in the fo	lowing box:
l l	lone.		

Date	e:December 7,2021		
	r Name:Zhiming Xiang_		
			n aberrant methylation levels revealed potential novel
Mar	nuscript number (if known):		-
relat	ted to the content of your n	nanuscript. "Related" mea	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third
to tr	_	ecessarily indicate a bias.	of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
	following questions apply touscript only.	o the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup	port for the work reporte	d in this manuscript without time limit. For all other items
the	time frame for disclosure is	the past 36 months.	a in this manascript without time initi. For an other items
the	time frame for disclosure is		
the	time frame for disclosure is	Name all entities with	Specifications/Comments
the	time frame for disclosure is	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
the	time frame for disclosure is	Name all entities with	Specifications/Comments
the	time frame for disclosure is	Name all entities with whom you have this relationship or indicate	Specifications/Comments (e.g., if payments were made to you or to your
the	time frame for disclosure is	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiation	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiation. None Time frame: pas	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiation	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiation. None Time frame: pas	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work

Consulting fees

5	Payment or honoraria for	None		
	lectures, presentations,			
	speakers bureaus,			
	manuscript writing or			
	educational events			
6	Payment for expert	None		
	testimony			
7	Support for attending meetings and/or travel	None		
8	Patents planned, issued or	None		
	pending			
9	Participation on a Data	None		
	Safety Monitoring Board or			
	Advisory Board			
10	Leadership or fiduciary role	None		
	in other board, society,			
	committee or advocacy			
11	group, paid or unpaid	NI		_
11	Stock or stock options	None		
				_
12	Descipt of aguinment	None		
12	Receipt of equipment, materials, drugs, medical	None		
	writing, gifts or other			_
	services			
13	Other financial or non-	None		
	financial interests			
				_
Plea	ase summarize the above co	nflict of interest in the f	ollowing box:	
N	lone.			